Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01101997
Other study ID # ZA10-001
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 30, 2010
Est. completion date December 8, 2010

Study information

Verified date August 2020
Source Zeltiq Aesthetics
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is being performed to reduce unwanted abdominal fat using a new applicator for the Zeltiq System.


Description:

The primary objective of the study is to achieve a discernable change to the contour of the abdominal area treated with the JUNO applicator that is consistent with that documented during a clinical study of a previous applicator used to treat lovehandles.


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date December 8, 2010
Est. primary completion date September 28, 2010
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Male or female subjects > 18 years of age. 2. Subject has clearly visible fat on the abdomen. 3. Subject has not had weight change exceeding 10 pounds in the preceding month. 4. Subject agrees to maintain their weight (i.e., within 5 pounds) by not making any major changes in their diet or lifestyle during the course of the study. 5. Subject has read and signed a written informed consent form. Exclusion Criteria: 1. Subject has had a surgical procedure(s) in the area of intended treatment in the past 6 months. 2. Subject has had an invasive fat reduction procedure (e.g., liposuction, abdominoplasty, mesotherapy) in the area of intended treatment within the past year. 3. Subject has had a non-invasive fat reduction procedure in the area of intended treatment within the past 6 months. 4. Subject has a known history of subcutaneous injections into the area of intended treatment (e.g., heparin, insulin) within the past month. 5. Subject has a known history of cryoglobulinemia, cold urticaria, or paroxysmal cold hemoglobinuria. 6. Subject has a known history of Reynaud's disease, or any known condition with a response to cold exposure that limits blood flow to the skin. 7. Subject has a history of bleeding disorder or is taking any medication that in the investigator's opinion may increase the subject's risk of bruising. 8. Subject body mass index (BMI) exceeds 40. BMI is defined as weight in pounds multiplied by 703 divided by the square of the height in inches. 9. Subject is taking or has taken diet pills or supplements within the past month. 10. Subject has any dermatological conditions or scars in the location of the treatment sites that may interfere with the treatment or evaluation. 11. Subject is pregnant or intending to become pregnant in the next 6 months. 12. Subject is lactating or has been lactating in the past 6 months. 13. Subject is unable or unwilling to comply with the study requirements. 14. Subject is currently enrolled in a clinical study of any other unapproved investigational drug or device. 15. Any other condition or laboratory value that would, in the professional opinion of the investigator, potentially affect the subject's response or the integrity of the data or would pose an unacceptable risk to the subject.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
The Zeltiq System
Noninvasive cooling is applied to the treatment area with a defined cooling rate and duration.

Locations

Country Name City State
United States Skin Care Physicians of Chestnut Hill Chestnut Hill Massachusetts
United States Flor Mayoral, M.D. Coral Gables Florida
United States Zel Skin and Laser Specialist LLC Edina Minnesota
United States Maryland Laser, Skin and Vein Institute Hunt Valley Maryland
United States Laser and Skin Surgery of Northern California Sacramento California

Sponsors (1)

Lead Sponsor Collaborator
Zeltiq Aesthetics

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of Pre-treatment Images Correctly Identified Change in the treated vs. untreated areas will be assessed by observation of changes in surface contour and/or fat volume by an independent photo review of pre-treatment and post-treatment images of the treated areas. Reviewers will be practicing dermatologists or plastic surgeons. All reviewers will be blinded to post-treatment vs. baseline untreated area. The order in which images will be presented will be randomized; for each subject placement of the baseline, pre-treatment image will be randomized for each pair of subject images. Reviewers will be asked to select the baseline photos for each subject photo series and record selections on a data collection form. The expected success rate is an average 80% correct identification by the three reviewers. 16 weeks
Secondary Change in the Fat Layer of the Treated Area as Measured by Ultrasound Change in the fat layer thickness will be calculated by comparison of pre-treatment and 16 week post-treatment ultrasound measurements taken in the area treated with the device, and in the adjacent untreated control area. The Sponsor's standardized techniques for obtaining ultrasound imaging will be used. Overall fat layer thickness changes were normalized for each subject by subtracting the change in control from the change in treated area to remove the influence of weight variations. Results indicate the fat layer reduction in mm. 16 weeks
Secondary Subject Satisfaction Subject satisfaction with the Zeltiq procedure as determined by the results of a subjects satisfaction questionnaire at the 16 week follow up visit. 16 weeks
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05256771 - Electrical Muscle Stimulation With 1064 nm Diode Laser and RF/PEMF for Non-invasive Body Contouring and Fat Reduction. N/A
Completed NCT03647748 - Effects of Green Light Therapy on Body Contouring and Cellulite N/A
Completed NCT03241563 - Subcutaneous Sodium Deoxycholate Injections With or Without Triamcinolone for Reduction of Submental Fat Phase 4